Downregulation of miR-221/222 enhances sensitivity of breast cancer cells to tamoxifen through upregulation of TIMP3.

abstract：:Interferon-gamma (IFN-γ) exhibits biological activities that are considered to have important roles in tumor suppression. Therefore, the IFN-γ gene is a potential candidate for in vivo cytokine gene therapy against skin cancer. The present study evaluated the efficacy of a hydrodynamics-based IFN-γ gene transfection f...

journal_title：Cancer gene therapy

authors： Ko JH,Jung BG,Park YS,Lee BJ

更新日期：2011-09-01 00:00:00

abstract：:In order to determine the potential of alternative splicing as a means of targeting the expression of therapeutic genes to tumor cells in vivo, a series of episomal plasmid-based "splice-activated gene expression" (pSAGE) vectors was generated, which contain minigene cassettes composed of various combinations of the t...

journal_title：Cancer gene therapy

authors： Hayes GM,Carpenito C,Davis PD,Dougherty ST,Dirks JF,Dougherty GJ

更新日期：2002-02-01 00:00:00

abstract：:We have developed unique replication-competent retroviral (RCR) vectors based on murine leukemia virus that provide improved efficiency of viral delivery, allow for long-term transgene expression and demonstrate an intrinsic selectivity for transduction of rapidly dividing tumor cells. The purpose of this study was to...

journal_title：Cancer gene therapy

authors： Kikuchi E,Menendez S,Ozu C,Ohori M,Cordon-Cardo C,Logg CR,Kasahara N,Bochner BH

更新日期：2007-03-01 00:00:00

abstract：:Sarcomas, or tumors of connective tissue, represent roughly 20% of childhood cancers. Although the cure rate for sarcomas in general has significantly improved in the last 10 years, there continue to be subgroups that are difficult to treat. High-grade or metastatic soft-tissue sarcomas and rhabdomyosarcomas (RMS) of ...

journal_title：Cancer gene therapy

authors： Ganjavi H,Gee M,Narendran A,Freedman MH,Malkin D

更新日期：2005-04-01 00:00:00

abstract：:Over the past several years we have obtained considerable evidence indicating that adenoviruses-expressing interferon α (Ad-IFNα) can overcome resistance to the IFNα protein itself. Since cancer cells infected with Ad-IFNα also show high perinuclear cytoplasmic IFNα expression, we were interested in whether endoplasmi...

journal_title：Cancer gene therapy

authors： Yang Z,Zhang XQ,Dinney CN,Benedict WF

更新日期：2011-09-01 00:00:00

abstract：:Adenoviral vectors are widely used in cancer gene therapy. After systemic administration however, the majority of the virus homes to the liver and the expressed transgene may cause hepatotoxicity. To restrict transgene expression to tumor cells, tumor- or tissue-specific promoters are utilized. The tumor antigen epith...

journal_title：Cancer gene therapy

authors： Gommans WM,van Eert SJ,McLaughlin PM,Harmsen MC,Yamamoto M,Curiel DT,Haisma HJ,Rots MG

更新日期：2006-02-01 00:00:00

abstract：:The purpose of this study was to determine the feasibility of cytokine gene delivery to lymphatic tissue using transduced bone marrow-derived cells. MBAE and pBABE retroviral vectors carrying the genes for murine interleukin-4 and the selection marker neomycin phosphotransferase (neo) were used to transduce bone marro...

journal_title：Cancer gene therapy

authors： Fiehn C,Wettschureck N,Krauthoff A,Haas R,Ho AD

更新日期：2000-08-01 00:00:00

abstract：:As an initial assessment of the feasibility of employing the adenovirus serotype 3 (Ad3) fiber knob as a locale for introducing a tropism-modifying motif, we generated an adenoviral vector containing a six-histidine tag genetically fused to the carboxy-terminus of the Ad3 fiber knob. The heterologous tag proved to be ...

journal_title：Cancer gene therapy

authors： Uil TG,Seki T,Dmitriev I,Kashentseva E,Douglas JT,Rots MG,Middeldorp JM,Curiel DT

更新日期：2003-02-01 00:00:00

abstract：:Retrospective analysis of data from 14,528 lung cancer patients with multiple primary malignant neoplasm (MPMN) revealed that 2.5% (364/14,528) were MPMN cases and 96.2% (350/364) were diagnosed with two primary malignancies, 3.6% (13/364) with three primary malignancies, and 0.3% (1/364) with four primary malignancie...

journal_title：Cancer gene therapy

authors： Wang H,Hou J,Zhang G,Zhang M,Li P,Yan X,Ma Z

更新日期：2019-11-01 00:00:00

abstract：:Myeloid leukemia (ML) is heterogeneous cancer classified by abnormal growth of myeloid cells due to genetic aberrations and mutations. It is generally categorized by clonal disorders of hematopoietic stem cells and differentiation. The molecular mechanism behind the myeloid malignancies is not yet known, but recent se...

journal_title：Cancer gene therapy

authors： Panagal M,S R SK,P S,M B,M K,Gopinathe V,Sivakumare P,Sekar D

更新日期：2018-08-01 00:00:00

abstract：:Treatment of metastatic tumors with engineered adenoviruses that replicate selectively in tumor cells is a new therapeutic approach in cancer. Systemic administration of these oncolytic adenoviruses lack metastatic targeting ability. The tumor stroma engrafting property of intravenously injected mesenchymal stem cells...

journal_title：Cancer gene therapy

authors： García-Castro J,Alemany R,Cascalló M,Martínez-Quintanilla J,Arriero Mdel M,Lassaletta A,Madero L,Ramírez M

更新日期：2010-07-01 00:00:00

abstract：:Due to the lack of early diagnostic and effective treatment modalities, hepatocellular carcinoma (HCC) is still the most lethal cancer with a high mortality on a global scale. Recent studies have highlighted the key roles of microRNAs (miRs) in HCC development. In the study, we attempted to investigate the potential r...

journal_title：Cancer gene therapy

authors： Si T,Ning X,Zhao H,Zhang M,Huang P,Hu Z,Yang L,Lin L

更新日期：2020-11-30 00:00:00

abstract：:Multicomponent lipoplexes have recently emerged as especially promising transfection candidates, as they are from 10 to 100 times more efficient than binary complexes usually employed for gene delivery purposes. Previously, we investigated a number of chemical-physical properties of DNA-lipid complexes that were propo...

journal_title：Cancer gene therapy

authors： Marchini C,Pozzi D,Montani M,Alfonsi C,Amici A,Candeloro De Sanctis S,Digman MA,Sanchez S,Gratton E,Amenitsch H,Fabbretti A,Gualerzi CO,Caracciolo G

更新日期：2011-08-01 00:00:00

abstract：:The human epidermal growth factor receptors 2, 3, and 4 (HER2, HER3, and HER4, respectively) are frequently overexpressed in many human cancers, and therefore may be potential targets for receptor-mediated gene transfer. To evaluate this possibility, we constructed a series of HER-targeted gene transfer vehicles by co...

journal_title：Cancer gene therapy

authors： Kern JA,Wakita R,Sliwkowski MX

更新日期：1999-11-01 00:00:00

abstract：:Macrophages plasticity is a key feature in cancer progression. Neoplastic cells can alter their immune functions and orient them into a pro-tumoral phenotype. In this context, we developed a new therapeutic strategy to switch macrophages phenotype and reactivate their anti-tumoral functions. We showed a dual activity ...

journal_title：Cancer gene therapy

authors： Rose M,Duhamel M,Aboulouard S,Kobeissy F,Tierny D,Fournier I,Rodet F,Salzet M

更新日期：2021-01-05 00:00:00

abstract：:The tumor suppressor protein p53 is a transcription factor that can positively regulate the expression of critical target genes involved in negative control of cell growth or induction of apoptosis; p53 is also able to suppress the transcription of other genes by virtue of its ability to bind components of the basal t...

journal_title：Cancer gene therapy

authors： Zhu J,Gao B,Zhao J,Balmain A

更新日期：2000-01-01 00:00:00

abstract：:The herpes simplex virus thymidine kinase (HSV-TK) gene is being developed in the treatment of many different types of tumors. The HSV-TK gene sensitizes tumor cells to the antiviral drug ganciclovir (GCV) and mediates the bystander effect in which unmodified tumor cells are killed as well. Although this approach has ...

journal_title：Cancer gene therapy

authors： Whartenby KA,Darnowski JW,Freeman SM,Yurasha K,Calabresi P

更新日期：1999-09-01 00:00:00

abstract：:The success of cancer gene therapies requiring in vivo gene transfer is severely hampered by the low efficacy of gene transfer, which has been difficult to improve. We therefore established a novel strategy to increase the share of transduced cells post gene transfer. We hypothesized that in vivo selection of tumor ce...

journal_title：Cancer gene therapy

authors： Unger MM,Wahl J,Ushmorov A,Buechele B,Simmet T,Debatin KM,Beltinger C

更新日期：2007-01-01 00:00:00

abstract：:Oncolytic herpes simplex virus (oHSV)-1-based vectors selectively replicate in tumor cells causing direct killing, that is, oncolysis, while sparing normal cells. The oHSVs are promising anticancer agents, but their efficacy, when used as single agents, leaves room for improvement. We hypothesized that combining the d...

journal_title：Cancer gene therapy

authors： Passer BJ,Cheema T,Wu S,Wu CL,Rabkin SD,Martuza RL

更新日期：2013-01-01 00:00:00

abstract：:Retroviral replicating vectors (RRVs) have achieved efficient tumor transduction and enhanced therapeutic benefit in a wide variety of cancer models. Here, we evaluated two different RRVs derived from amphotropic murine leukemia virus (AMLV) and gibbon ape leukemia virus (GALV), which utilize different cellular recept...

journal_title：Cancer gene therapy

authors： Kubo S,Takagi-Kimura M,Kasahara N

更新日期：2019-02-01 00:00:00

abstract：:The fact that glioblastomas, which are one of the most devastating cancers, frequently express the Delta-EGFR (epithelial growth factor receptor) also called mutant variant III of EGFR (EGFRvIII) suggests that this cancer cell-specific receptor might serve as an ideal target for cancer therapy. To assess its potential...

journal_title：Cancer gene therapy

authors： Piao Y,Jiang H,Alemany R,Krasnykh V,Marini FC,Xu J,Alonso MM,Conrad CA,Aldape KD,Gomez-Manzano C,Fueyo J

更新日期：2009-03-01 00:00:00

abstract：:A phase I clinical trial using autologous, IL-7 gene-modified tumor cells in patients with disseminated melanoma has been recently completed. Although no major clinical responses were observed, increased antitumor cytotoxicity was measured in postvaccine peripheral blood lymphocytes in a subset of treated patients. To...

journal_title：Cancer gene therapy

authors： Carsana M,Tragni G,Nicolini G,Bersani I,Parmiani G,Anichini A,Sun YS,Möller P,Schadendorf D,Sensi ML

更新日期：2002-03-01 00:00:00

abstract：:The Holliday Junction-Recognition Protein (HJURP) was reported as overexpressed in several cancers and also strongly correlated with poor prognosis of patients, especially in glioblastoma (GBM), the most common and deadly type of primary brain tumor. HJURP is responsible for loading the histone H3 variant-the Centrome...

journal_title：Cancer gene therapy

authors： Serafim RB,Cardoso C,Di Cristofaro LFM,Pienna Soares C,Araújo Silva W Jr,Espreafico EM,Paçó-Larson ML,Price BD,Valente V

更新日期：2020-05-01 00:00:00

abstract：:Immune responses to tumor-associated antigens are often dampened by a tumor-induced state of immune anergy. Previous work has attempted to overcome tumor-induced T-cell anergy by the direct injection of vectors carrying the genes encoding one of a variety of cytokines. We hypothesised that the polyclonal stimulation o...

journal_title：Cancer gene therapy

authors： Paul S,Regulier E,Rooke R,Stoeckel F,Geist M,Homann H,Balloul JM,Villeval D,Poitevin Y,Kieny MP,Acres RB

更新日期：2002-05-01 00:00:00

abstract：:Melanoma incidence is growing at a faster rate than any other human malignancy. Wild-type (wt) p53 is important in both G(1) and G(2) cell cycle arrest, and cyclin D1 (CD1) is necessary for G(1)-->S progression in melanoma cells. We reported that an adenoviral vector containing wt p53 significantly reduced [(3)H]thymi...

journal_title：Cancer gene therapy

authors： Sauter ER,Takemoto R,Litwin S,Herlyn M

更新日期：2002-10-01 00:00:00

abstract：:The present study was designed to investigate the upstream transcription factors (TFs) and the signature genes in cholangiocarcinoma (CCA), providing better clues on the regulatory mechanisms and therapeutic applications. Gene expression data sets of CCA were searched in the Gene Expression Omnibus database for integr...

journal_title：Cancer gene therapy

authors： Yang L,Feng S,Yang Y

更新日期：2016-12-01 00:00:00

abstract：:The antitumor activity of a recombinant canarypox virus expressing wild type murine p53 (ALVAC-p53) was investigated in two murine syngeneic tumors harboring an endogenous p53 mutation (CMS4 and TS/A). Direct intratumor injections of ALVAC-p53 in CMS4 pre-established subcutaneous tumors induced total tumor regression ...

journal_title：Cancer gene therapy

authors： Odin L,Favrot M,Poujol D,Michot JP,Moingeon P,Tartaglia J,Puisieux I

更新日期：2001-02-01 00:00:00

abstract：:Lung metastases are a frequent complication of osteosarcoma and a treatment that would reduce the severity of this complication would be of great benefit to patients. We have used a formulation consisting of polyethyleneimine (PEI) and a p53 gene administered in aerosol to treat established lung micrometastases as a m...

journal_title：Cancer gene therapy

authors： Densmore CL,Kleinerman ES,Gautam A,Jia SF,Xu B,Worth LL,Waldrep JC,Fung YK,T'Ang A,Knight V

更新日期：2001-09-01 00:00:00

abstract：:Although early stage cholangiocarcinoma (CC) can be cured by surgical extirpation, the options for treatment of advanced stage CC are very few and suboptimal. Oncolytic virotherapy using replication-competent vaccinia virus (VACV) is a promising new strategy to treat human cancers. The ability of oncolytic VACV GLV-1h...

journal_title：Cancer gene therapy

authors： Pugalenthi A,Mojica K,Ady JW,Johnsen C,Love D,Chen NG,Aguilar RJ,Szalay AA,Fong Y

更新日期：2015-12-01 00:00:00

abstract：:RNA interference is an endogenous gene-silencing mechanism that involves double-stranded RNA-mediated sequence-specific mRNA degradation. The discovery of this pathway together with the elucidation of the structure and function of short interfering RNAs--the effector molecules of RNA interference--has had an enormous ...

journal_title：Cancer gene therapy

authors： Karagiannis TC,El-Osta A

更新日期：2005-10-01 00:00:00